PT3472165T - Derivados de n-(fenil substituído)-sulfonamida como inibidores da quinase - Google Patents
Derivados de n-(fenil substituído)-sulfonamida como inibidores da quinaseInfo
- Publication number
- PT3472165T PT3472165T PT177320751T PT17732075T PT3472165T PT 3472165 T PT3472165 T PT 3472165T PT 177320751 T PT177320751 T PT 177320751T PT 17732075 T PT17732075 T PT 17732075T PT 3472165 T PT3472165 T PT 3472165T
- Authority
- PT
- Portugal
- Prior art keywords
- phenyl
- substituted
- kinase inhibitors
- sulfonamide derivatives
- sulfonamide
- Prior art date
Links
- -1 N-(substituted-phenyl)-sulfonamide Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16175386 | 2016-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3472165T true PT3472165T (pt) | 2023-12-12 |
Family
ID=56148248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177320751T PT3472165T (pt) | 2016-06-21 | 2017-06-19 | Derivados de n-(fenil substituído)-sulfonamida como inibidores da quinase |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10561660B2 (pt) |
| EP (1) | EP3472165B1 (pt) |
| JP (1) | JP6867417B2 (pt) |
| KR (1) | KR102500416B1 (pt) |
| CN (1) | CN109311894B (pt) |
| AU (1) | AU2017279878B9 (pt) |
| CA (1) | CA3029097A1 (pt) |
| DK (1) | DK3472165T3 (pt) |
| ES (1) | ES2964781T3 (pt) |
| FI (1) | FI3472165T3 (pt) |
| HU (1) | HUE064919T2 (pt) |
| IL (1) | IL263739B (pt) |
| MX (1) | MX2018016419A (pt) |
| PT (1) | PT3472165T (pt) |
| RU (1) | RU2753520C2 (pt) |
| SI (1) | SI3472165T1 (pt) |
| WO (1) | WO2017220477A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109311894B (zh) | 2016-06-21 | 2022-03-22 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的n-(取代的-苯基)-磺酰胺衍生物 |
| US20220315594A1 (en) * | 2019-08-09 | 2022-10-06 | Ohm Oncology | Method of synthesis of compound for dual inhibition of jak2 and bet |
| KR20210056827A (ko) * | 2019-11-11 | 2021-05-20 | 일동제약(주) | 신규한 벤젠설폰아미드 유도체 및 그의 용도 |
| BR112022016072A2 (pt) * | 2020-02-17 | 2022-10-04 | Alesta Therapeutics BV | Compostos moduladores de gcn2, sal farmaceuticamente aceitável, seus usos, e composição farmacêutica |
| MX2022013984A (es) | 2020-05-08 | 2023-01-30 | Halia Therapeutics Inc | Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7). |
| CN111454261A (zh) * | 2020-05-27 | 2020-07-28 | 南京普锐达医药科技有限公司 | 一种4-氯吡咯并嘧啶化合物的合成方法 |
| KR20230121758A (ko) * | 2020-11-18 | 2023-08-21 | 데시페라 파마슈티칼스, 엘엘씨. | Gcn2 및 perk 키나제 억제제 및 그의 사용 방법 |
| WO2022212326A1 (en) | 2021-03-29 | 2022-10-06 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| CA3214042A1 (en) | 2021-04-05 | 2022-10-13 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2023025912A1 (en) | 2021-08-25 | 2023-03-02 | Alesta Therapeutics BV | Use of gcn2 inhibitors in treating cancer |
| WO2023102228A1 (en) * | 2021-12-03 | 2023-06-08 | Deciphera Pharmaceuticals, Llc | Heterocyclic compopunds as gcn2 and perk kinase inhibitors |
| WO2023196659A1 (en) * | 2022-04-08 | 2023-10-12 | Alesta Therapeutics BV | Gcn2 modulator compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998041525A1 (en) * | 1997-03-19 | 1998-09-24 | Basf Aktiengesellschaft | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
| TR200101395T2 (tr) * | 1998-09-18 | 2001-11-21 | Basf Ag. | Kinaz engelleyiciler olarak 4-Aminopyrrolopyrimidin'ler |
| GB0625827D0 (en) * | 2006-12-22 | 2007-02-07 | Astex Therapeutics Ltd | New compounds |
| JP5819195B2 (ja) | 2008-10-16 | 2015-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 融合環ヘテロアリールキナーゼ阻害剤 |
| UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| MD20150048A2 (ro) * | 2012-10-16 | 2015-10-31 | Almirall S.A. | Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K |
| JP6268276B2 (ja) | 2013-04-04 | 2018-01-24 | ヤンセン ファーマシューティカ エヌ．ベー． | ＰＥＲＫ阻害剤としての新規なＮ（２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジン−５−イル）−４−キナゾリンアミン誘導体およびＮ−（２，３−ジヒドロ−１Ｈ−インドール−５−イル）−４−キナゾリンアミン誘導体 |
| CA2912568A1 (en) * | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| EP3116877A1 (en) | 2014-03-11 | 2017-01-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Chemical compounds acting as perk inhibitors |
| CN109311894B (zh) * | 2016-06-21 | 2022-03-22 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的n-(取代的-苯基)-磺酰胺衍生物 |
-
2017
- 2017-06-19 CN CN201780038709.2A patent/CN109311894B/zh active Active
- 2017-06-19 WO PCT/EP2017/064904 patent/WO2017220477A1/en unknown
- 2017-06-19 AU AU2017279878A patent/AU2017279878B9/en active Active
- 2017-06-19 PT PT177320751T patent/PT3472165T/pt unknown
- 2017-06-19 EP EP17732075.1A patent/EP3472165B1/en active Active
- 2017-06-19 KR KR1020197001839A patent/KR102500416B1/ko active IP Right Grant
- 2017-06-19 ES ES17732075T patent/ES2964781T3/es active Active
- 2017-06-19 DK DK17732075.1T patent/DK3472165T3/da active
- 2017-06-19 RU RU2019101002A patent/RU2753520C2/ru active
- 2017-06-19 JP JP2018566910A patent/JP6867417B2/ja active Active
- 2017-06-19 CA CA3029097A patent/CA3029097A1/en active Pending
- 2017-06-19 SI SI201731456T patent/SI3472165T1/sl unknown
- 2017-06-19 FI FIEP17732075.1T patent/FI3472165T3/fi active
- 2017-06-19 HU HUE17732075A patent/HUE064919T2/hu unknown
- 2017-06-19 US US16/312,061 patent/US10561660B2/en active Active
- 2017-06-19 MX MX2018016419A patent/MX2018016419A/es unknown
-
2018
- 2018-12-16 IL IL263739A patent/IL263739B/en unknown
-
2019
- 2019-12-19 US US16/721,267 patent/US10918642B2/en active Active
-
2021
- 2021-01-04 US US17/140,471 patent/US11491158B2/en active Active
-
2022
- 2022-09-29 US US17/936,576 patent/US11833153B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210128563A1 (en) | 2021-05-06 |
| AU2017279878B2 (en) | 2021-04-01 |
| KR102500416B1 (ko) | 2023-02-17 |
| US10561660B2 (en) | 2020-02-18 |
| RU2753520C2 (ru) | 2021-08-17 |
| AU2017279878B9 (en) | 2021-04-29 |
| US10918642B2 (en) | 2021-02-16 |
| US11491158B2 (en) | 2022-11-08 |
| SI3472165T1 (sl) | 2024-02-29 |
| AU2017279878A1 (en) | 2019-01-31 |
| US20230107393A1 (en) | 2023-04-06 |
| CN109311894A (zh) | 2019-02-05 |
| JP6867417B2 (ja) | 2021-04-28 |
| MX2018016419A (es) | 2019-09-09 |
| RU2019101002A (ru) | 2020-07-21 |
| HUE064919T2 (hu) | 2024-04-28 |
| IL263739B (en) | 2022-02-01 |
| EP3472165A1 (en) | 2019-04-24 |
| JP2019521996A (ja) | 2019-08-08 |
| KR20190020104A (ko) | 2019-02-27 |
| DK3472165T3 (da) | 2023-12-11 |
| ES2964781T3 (es) | 2024-04-09 |
| US20200121686A1 (en) | 2020-04-23 |
| FI3472165T3 (fi) | 2023-12-11 |
| US20190201406A1 (en) | 2019-07-04 |
| IL263739A (en) | 2019-01-31 |
| CA3029097A1 (en) | 2017-12-28 |
| WO2017220477A1 (en) | 2017-12-28 |
| EP3472165B1 (en) | 2023-09-06 |
| US11833153B2 (en) | 2023-12-05 |
| RU2019101002A3 (pt) | 2020-09-30 |
| CN109311894B (zh) | 2022-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263739B (en) | History of n-(converted-phenyl)-sulfonamide as kinase inhibitors | |
| HK1245244A1 (zh) | 作爲激酶抑制劑的雜環酰胺 | |
| IL268614B (en) | Aminotriazolopyridines as kinase inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| IL274207A (en) | Aminoimidazopyridazines as kinase inhibitors | |
| IL304547A (en) | 3-substituted benzamide derivatives as kinase inhibitors | |
| IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
| MA44607A (fr) | Inhibiteurs de kinase | |
| EP3347357A4 (en) | HETEROCYCLIC KINASEINHIBITORS OF THE TEC FAMILY | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| GB201613945D0 (en) | Compounds useful as kinase inhibitors | |
| TH1501004620A (th) | เฮทเทอโรไซคลิก เอไมด์ ในรูปสารยับยั้งไคเนส |